参考文献（下滑查看）：

[1]GE Stein , WA Craig . Tigecycline: a critical analysis[J]. Clin Infect Dis, 2006, 43(4):518-524. DOI: 10.1086/505494 .

[2]D Schnappinger , W Hillen . Tetracyclines: antibiotic action, uptake, and resistance mechanisms[J]. Arch Microbiol, 1996, 165(6):359-369. DOI: 10.1007/s002030050339 .

[3]TH Grossman . Tetracycline antibiotics and resistance[J]. Cold Spring Harb Perspect Med, 2016, 6(4):a025387. DOI: 10.1101/cshperspect.a025387 .

[4]S Yaghoubi , AO Zekiy , M Krutova , et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review[J]. Eur J Clin Microbiol Infect Dis, 2022, 41(7):1003-1022. DOI: 10.1007/s10096-020-04121-1 .

[5]中国医疗保健国际交流促进会临床微生物与感染分会, 中华医学会检验医学分会临床微生物学组, 中华医学会微生物学与免疫学分会临床微生物学组. 多黏菌素类与替加环素及头孢他啶/阿维巴坦药敏方法和报告专家共识[J]. 中华检验医学杂志, 2020, 43(10):964-972. DOI: 10.3760/cma.j.cn114452-20200719-00619 .

[6]P Wayne . Performance standards for antimicrobial susceptibility testingagents[EB/OL]. [ 2023-02-01]. https://clsi.org/media/3481/m100ed30_sample.

[7]全国细菌耐药监测网. 全国细菌耐药监测网2014—2019年细菌耐药性监测报告[J]. 中国感染控制杂志, 2021, 20(1):15-30. DOI: 10.12138/j.issn.1671-9638.20216170 .

[8]I Chopra . New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors[J]. Drug Resist Updat, 2002, 5(3-4):119-125. DOI: 10.1016/s1368-7646(02)00051-1 .

[9]董璐瑶, 李国庆, 游雪甫, 等. 奥玛环素研究进展[J]. 中国医药生物技术, 2020, 15(1):48-56. DOI: 10.3969/j.issn.1673-713X.2020.01.009 .

[10]GG Zhanel , D Cheung , H Adam , et al. Review of eravacycline, a novel fluorocycline antibacterial agent[J]. Drugs, 2016, 76(5):567-588. DOI: 10.1007/s40265-016-0545-8 .

[11]TM Duane , JM Huston , M Collom , et al. Surgical infection society 2020 updated guidelines on the management of complicated skin and soft tissue infections[J]. Surg Infect (Larchmt), 2021, 22(4):383-399. DOI: 10.1089/sur.2020.436 .

[12]FM Abrahamian , G Sakoulas , E Tzanis , et al. Omadacycline for acute bacterial skin and skin structure infections[J]. Clin Infect Dis, 2019, 69(Suppl 1):S23-S32. DOI: 10.1093/cid/ciz396 .

[13]W O′Riordan , C Cardenas , E Shin , et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial[J]. Lancet Infect Dis, 2019, 19(10):1080-1090. DOI: 10.1016/S1473-3099(19)30275-0 .

[14]中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41(4): 255-280. DOI: 10.3760/cma.j.issn.1001-0939.2018.04.006 .

[15]C Tanaseanu , C Bergallo , O Teglia , et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia[J]. Diagn Microbiol Infect Dis, 2008, 61(3):329-338. DOI: 10.1016/j.diagmicrobio.2008.04.009 .

[16]KP Connors , ST Housman , JS Pope , et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women[J]. Antimicrob Agents Chemother, 2014, 58(4):2113-2118. DOI: 10.1128/AAC.02036-13 .

[17]B Ternes , F Wagenlehner . Guideline-based treatment of urinary tract infections[J]. Urologe A, 2020, 59(5):550-558. DOI: 10.1007/s00120-020-01174-0 .

[18]张建初, 辛建保, 向菲, 等. 注射用盐酸米诺环素治疗呼吸和泌尿系感染的多中心随机对照临床研究[J]. 中国抗生素杂志, 2008, 33(8):483-486, 498.

[19]G Wu , T Abraham , N Saad . Role of tigecycline for the treatment of urinary tract infections[J]. J Pharm Technol, 2014, 30(3):87-92. DOI: 10.1177/8755122513519332 .

[20]KB Waites , DM Crabb , Y Liu , et al. In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human mycoplasmas and ureaplasmas[J]. Antimicrob Agents Chemother, 2016, 60(12):7502-7504. DOI: 10.1128/AAC.01734-16 .

[21]GE Kenny , FD Cartwright . Susceptibilities of mycoplasma hominis, m. pneumoniae, and ureaplasma urealyticum to gar-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones[J]. Antimicrob Agents Chemother, 2001, 45(9):2604-2608. DOI: 10.1128/AAC.45.9.2604-2608.2001 .

[22]PM Roblin , MR Hammerschlag . In vitro activity of GAR-936 against chlamydia pneumoniae and chlamydia trachomatis[J]. Int J Antimicrob Agents, 2000, 16(1):61-63. DOI: 10.1016/s0924-8579(00)00198-9 .

[23]BA Cunha . The atypical pneumonias: clinical diagnosis and importance[J]. Clin Microbiol Infect, 2006, 12Suppl 3∶12-24. DOI: 10.1111/j.1469-0691.2006.01393.x .

[24]A Assaidi , M Ellouali , H Latrache , et al. Antimicrobial susceptibility patterns of legionella spp. strains isolated from water systems in Morocco[J]. Microb Drug Resist, 2020, 26(8):991-996. DOI: 10.1089/mdr.2019.0218 .

[25]J Dubois , M Dubois , JF Martel . In vitro and intracellular activities of omadacycline against legionella pneumophila[J]. Antimicrob Agents Chemother, 2020, 64(5). DOI: 10.1128/AAC.01972-19 .

[26]D Felmingham . Tigecyclin–the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline[J]. J Chemother, 2005, 17Suppl 1:5-11. DOI: 10.1179/joc.2005.17.Supplement-1.5 .

[27]A Kaushik , NC Ammerman , O Martins , et al. In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of mycobacterium abscessus[J]. Antimicrob Agents Chemother, 2019, 63(6). DOI: 10.1128/AAC.00470-19 .

[28]BA Brown-Elliott , RJ Wallace Jr. In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria[J]. Antimicrob Agents Chemother, 2021, 65(3). DOI: 10.1128/AAC.01947-20 .

[29]《中华传染病杂志》编辑委员会. 布鲁菌病诊疗专家共识[J]. 中华传染病杂志, 2017, 35(12):705-710. DOI: 10.3760/cma.j.issn.1000-6680.2017.12.001 .

[30]J Solís García del Pozo , J Solera . Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis[J]. PLoS One, 2012, 7(2):e32090. DOI: 10.1371/journal.pone.0032090 .

[31]K Vasilev , G Reshedko , R Orasan , et al. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including enterobacter species, acinetobacter baumannii and Klebsiella pneumoniae[J]. J Antimicrob Chemother, 2008, 62Suppl 1:i29-40. DOI: 10.1093/jac/dkn249 .

[32]AT Freire , V Melnyk , MJ Kim , et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia[J]. Diagn Microbiol Infect Dis, 2010, 68(2):140-151. DOI: 10.1016/j.diagmicrobio.2010.05.012 .

[33]L Zha , L Pan , J Guo , et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis[J]. Adv Ther, 2020, 37(3):1049-1064. DOI: 10.1007/s12325-020-01235-y .

[34]J Ramirez , N Dartois , H Gandjini , et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia[J]. Antimicrob Agents Chemother, 2013, 57(4):1756-1762. DOI: 10.1128/AAC.01232-12 .

[35]DE Wiskirchen , P Koomanachai , AM Nicasio , et al. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase[J]. Antimicrob Agents Chemother, 2011, 55(4):1420-1427. DOI: 10.1128/AAC.01253-10 .

[36]FG De Rosa , S Corcione , G Di Perri , et al. Re-defining tigecycline therapy[J]. New Microbiol, 2015, 38(2):121-136.

[37]SY Hou , D Wu , XH Feng . Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae: a systematic review and meta-analysis[J]. J Glob Antimicrob Resist, 2020, 23:197-202. DOI: 10.1016/j.jgar.2020.08.024 .

[38]周华, 李光辉, 卓超, 等. 中国嗜麦芽窄食单胞菌感染诊治和防控专家共识[J]. 中华医学杂志, 2013, 93(16):1203-1213. DOI: 10.3760/cma.j.issn.0376-2491.2013.16.002 .

[39]A Hobbs , MS Gelfand , KO Cleveland , et al. A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals[J]. J Glob Antimicrob Resist, 2022, 29:430-433. DOI: 10.1016/j.jgar.2021.10.020 .

[40]中华医学会外科学分会外科感染与重症医学学组, 中国医师协会外科医师分会肠瘘外科医师专业委员会. 中国腹腔感染诊治指南(2019版)[J]. 中国实用外科杂志, 2020, 40(1):1-16. DOI: 10.19538/j.cjps.issn1005-2208.2020.01.01 .

[41]JS Solomkin , J Gardovskis , K Lawrence , et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections[J]. Clin Infect Dis, 2019, 69(6):921-929. DOI: 10.1093/cid/ciy1029 .

[42]K Eljaaly , JK Ortwine , M Shaikhomer , et al. Efficacy and safety of eravacycline: a meta-analysis[J]. J Glob Antimicrob Resist, 2021, 24:424-428. DOI: 10.1016/j.jgar.2021.02.009 .

[43]J Solomkin , D Evans , A Slepavicius , et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial[J]. JAMA Surg, 2017, 152(3):224-232. DOI: 10.1001/jamasurg.2016.4237 .

[44]LJ Scott . Eravacycline: a review in complicated intra-abdominal infections[J]. Drugs, 2019, 79(3):315-324. DOI: 10.1007/s40265-019-01067-3 .

[45]PD Tamma , SL Aitken , RA Bonomo , et al. Infectious diseases society of america guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)[J]. Clin Infect Dis, 2021, 72(7): e169-e183. 10.1093/cid/ciaa1478 .

[46]MJ Satlin , CJ Kubin , JS Blumenthal , et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine[J]. Antimicrob Agents Chemother, 2011, 55(12):5893-5899. DOI: 10.1128/AAC.00387-11 .

[47]YX Liu , KJ Le , HY Shi , et al. Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review[J]. Transl Androl Urol, 2021, 10(1):292-299. DOI: 10.21037/tau-20-959 .

[48]JA Karlowsky , J Steenbergen , GG Zhanel . Microbiology and preclinical review of omadacycline[J]. Clin Infect Dis, 2019, 69(Suppl 1):S6-S15. DOI: 10.1093/cid/ciz395 .

[49]JS Overcash , P Bhiwandi , L Garrity-Ryan , et al. Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: results from a phase 1b study[J]. Antimicrob Agents Chemother, 2019, 63(5)DOI: 10.1128/AAC.02083-18 .

[50]Tetraphase. Tetraphase announces top-line results from IGNITE2 phase 3 clinical trial of eravacycline in cUTI [EB/OL]. [ 2023-02-01]. https://www.fiercebiotech.com/biotech/tetraphase-announces-top-line-results-from-ignite2-phase-3-clinical-trial-of-eravacycline.

[51]陈玥, 李佳安, 朱曼, 等. 替加环素鞘内/脑室内给药治疗多重耐药菌颅内感染的文献分析[J]. 中国临床药学杂志, 2021, 30(1):46-50. DOI: 10.19577/j.1007-4406.2021.01.012 .

[52]中国医师协会神经外科医师分会神经重症专家委员会, 北京医学会神经外科学分会神经外科危重症学组. 神经外科中枢神经系统感染诊治中国专家共识(2021版)[J]. 中华神经外科杂志, 2021, 37(1):2-15. DOI: 10.3760/cma.j.cn112050-20200831-00480 .

[53]OR Sipahi , S Mermer , T Demirdal , et al. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study[J]. Clin Neurol Neurosurg, 2018, 172:31-38. DOI: 10.1016/j.clineuro.2018.06.008 .

[54]邱炳辉, 漆松涛, 曾浩, 等. 神经外科ICU耐药鲍曼不动杆菌颅内感染的治疗[J]. 中华神经外科杂志, 2014, 30(6):586-588. DOI: 10.3760/cma.j.issn.1001-2346.2014.06.014 .

[55]CL Sy , PY Chen , CW Cheng , et al. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms[J]. J Microbiol Immunol Infect, 2022, 55(3):359-386. DOI: 10.1016/j.jmii.2022.02.001 .

[56]CA Liang , YC Lin , PL Lu , et al. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii[J]. Clin Microbiol Infect, 2018, 24(8):908.e1-908.e7. DOI: 10.1016/j.cmi.2017.10.033 .

[57]YT Lee , YC Wang , SC Kuo , et al. Multicenter study of clinical features of breakthrough acinetobacter bacteremia during carbapenem therapy[J]. Antimicrob Agents Chemother, 2017, 61(9). DOI: 10.1128/AAC.00931-17 .

[58]A Cheng , YC Chuang , HY Sun , et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant acinetobacter baumannii bacteremia: a multicenter prospective observational study[J]. Crit Care Med, 2015, 43(6):1194-1204. DOI: 10.1097/CCM.0000000000000933 .

[59]JN O′Donnell , V Putra , TP Lodise . Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options?[J]. Pharmacotherapy, 2021, 41(9):762-780. DOI: 10.1002/phar.2607 .

[60]PD Tamma , SL Aitken , RA Bonomo , et al. Infectious diseases society of america guidance on the treatment of ampc β-lactamase-producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections[J]. Clin Infect Dis, 2022, 74(12):2089-2114. DOI: 10.1093/cid/ciab1013 .

[61]GA Denys , SM Callister , MJ Dowzicky . Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)[J]. Ann Clin Microbiol Antimicrob, 2013, 12:24. DOI: 10.1186/1476-0711-12-24 .

[62]H Wu , H Feng , L He , et al. In Vitro Activities of tigecycline in combination with amikacin or colistin against carbapenem-resistant acinetobacter baumannii[J]. Appl Biochem Biotechnol, 2021, 193(12):3867-3876. DOI: 10.1007/s12010-021-03664-z .

[63]A Sertcelik , I Baran , E Akinci , et al. Synergistic activities of colistin combinations with meropenem, sulbactam, minocycline, disodium fosfomycin, or vancomycin against different clones of carbapenem-resistant acinetobacter baumannii strains[J]. Microb Drug Resist, 2020, 26(5):429-433. DOI: 10.1089/mdr.2019.0088 .

[64]WH Sheng , JT Wang , SY Li , et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU[J]. Diagn Microbiol Infect Dis, 2011, 70(3):380-386. DOI: 10.1016/j.diagmicrobio.2011.03.003 .

[65]KR Peck , MJ Kim , JY Choi , et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin-or tigecycline-resistant isolates[J]. J Med Microbiol, 2012, 61(Pt 3):353-360. DOI: 10.1099/jmm.0.036939-0 .

[66]M Beganovic , KE Daffinee , MK Luther , et al. Minocycline alone and in combination with polymyxin b, meropenem, and sulbactam against carbapenem-susceptible and-resistant acinetobacter baumannii in an in vitro pharmacodynamic model[J]. Antimicrob Agents Chemother, 2021, 65(3)DOI: 10.1128/AAC.01680-20 .

[67]GG Rao , NS Ly , J Diep , et al. Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii[J]. Int J Antimicrob Agents, 2016, 48(3):331-336. DOI: 10.1016/j.ijantimicag.2016.06.006 .

[68]PC Fragkou , G Poulakou , A Blizou , et al. The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant acinetobacter baumannii: a systematic review of clinical evidence[J]. Microorganisms, 2019, 7(6)DOI: 10.3390/microorganisms7060159 .

[69]H Seok , WS Choi , S Lee , et al. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea[J]. J Glob Antimicrob Resist, 2021, 24:429-439. DOI: 10.1016/j.jgar.2021.01.018 .

[70]AS Chapman , JS Bakken , SM Folk , et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis–United States: a practical guide for physicians and other health-care and public health professionals[J]. MMWR Recomm Rep, 2006, 55(RR-4):1-27.

[71]R Cross , C Ling , NP Day , et al. Revisiting doxycycline in pregnancy and early childhood–time to rebuild its reputation?[J]. Expert Opin Drug Saf, 2016, 15(3):367-382. DOI: 10.1517/14740338.2016.1133584 .

[72]HM Biggs , CB Behravesh , KK Bradley , et al. Diagnosis and management of tickborne rickettsial diseases: rocky mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis-United States[J]. MMWR Recomm Rep, 2016, 65(2):1-44. DOI: 10.15585/mmwr.rr6502a1 .

[73]GP Wormser , RJ Dattwyler , ED Shapiro , et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2006, 43(9):1089-1134. DOI: 10.1086/508667 .

[74]H Pöyhönen , M Nurmi , V Peltola , et al. Dental staining after doxycycline use in children[J]. J Antimicrob Chemother, 2017, 72(10):2887-2890. DOI: 10.1093/jac/dkx245 .

[75]SR Todd , FS Dahlgren , MS Traeger , et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever[J]. J Pediatr, 2015, 166(5):1246-1251. DOI: 10.1016/j.jpeds.2015.02.015 .

[76]WA Peters 3rd, PY Liu , RJ Barrett 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix[J]. J Clin Oncol, 2000, 18(8):1606-1613. DOI: 10.1200/JCO.2000.18.8.1606 .

[77]JM Korth-Bradley , SJ Baird-Bellaire , AA Patat , et al. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis[J]. J Clin Pharmacol, 2011, 51(1):93-101. DOI: 10.1177/0091270010363477 .

[78]SJ Kovacs , L Ting , J Praestgaard , et al. An open-label study of the impact of hepatic impairment on the pharmacokinetics and safety of single oral and intravenous doses of omadacycline[J]. Antimicrob Agents Chemother, 2020, 64(11). DOI: 10.1128/AAC.01650-20 . 

[79]李俊. 临床药理学[M]. 4版. 北京:人民卫生出版社, 2008.

[80]贾蓓, 卓超, 黄文祥, 等. 注射用盐酸多西环素随机对照治疗细菌性感染多中心临床研究[J]. 重庆医科大学学报, 2007, 32(9):963-968, 973. DOI: 10.3969/j.issn.0253-3626.2007.09.018 .

[81]韩朝宏, 梁月冬. 米诺环素不良反应的国内文献综述[J]. 药物流行病学杂志, 2001, 10(3):143-144. DOI: 10.3969/j.issn.1005-0698.2001.03.012 .

[82]李春钰, 贾自力, 邢丽秋. 北京地区2013~2018年替加环素不良反应回顾性分析[J]. 药物流行病学杂志, 2019, 28(9):581-585.

[83]钟雪, 陈东科, 许宏涛, 等. 替加环素研究新进展[J]. 中国抗生素杂志, 2015, 40(11):870-875. DOI: 10.3969/j.issn.1001-8689.2015.11.015 .

[84]N Cui , H Cai , Z Li , et al. Tigecycline-induced coagulopathy: a literature review[J]. Int J Clin Pharm, 2019, 41(6):1408-1413. DOI: 10.1007/s11096-019-00912-5 .

[85]HA Hakeam , Z Al Duhailib . Tigecycline-induced coagulopathy: a literature review[J]. Int J Clin Pharm, 2020, 42(3):846-847. DOI: 10.1007/s11096-020-00974-w .

[86]A Markham , SJ Keam . Omadacycline: first global approval[j]. drugs, 2018, 78(18):1931-1937. DOI: 10.1007/s40265-018-1015-2 .

[87]SH Lan , SP Chang , CC Lai , et al. The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2019, 98(51):e18426. DOI: 10.1097/MD.0000000000018426 .

[88]JS Solomkin , A Sway , K Lawrence , et al. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance[J]. Future Microbiol, 2019, 14:1293-1308. DOI: 10.2217/fmb-2019-0135 .

[89]LA Hamilton , AJ Guarascio . Tetracycline allergy[J]. Pharmacy (Basel), 2019, 7(3). DOI: 10.3390/pharmacy7030104 .

[90]JW Jang , YJ Bae , YG Kim , et al. A case of anaphylaxis to oral minocycline[J]. J Korean Med Sci, 2010, 25(8):1231-1233. DOI: 10.3346/jkms.2010.25.8.1231 .

[91]B Lebrun-Vignes , C Kreft-Jais , A Castot , et al. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature[J]. Br J Dermatol, 2012, 166(6):1333-1341. DOI: 10.1111/j.1365-2133.2012.10845.x .

[92]O Correia , L Delgado , J Polónia . Genital fixed drug eruption: cross-reactivity between doxycycline and minocycline[J]. Clin Exp Dermatol, 1999, 24(2):137. DOI: 10.1046/j.1365-2230.1999.00436.x .

[93]HL Chan , SN Wong , FL Lo . Tetracycline-induced fixed drug eruptions: influence of dose and structure of tetracyclines[J]. J Am Acad Dermatol, 1985, 13(2Pt 1):302-304. DOI: 10.1016/s0190-9622(85)80289-9 .

[94]G Fan , L Jin , H Bai , et al. Safety and efficacy of tigecycline in intensive care unit patients based on therapeutic drug monitoring[J]. Ther Drug Monit, 2020, 42(6):835-840. DOI: 10.1097/FTD.0000000000000784 .

[95]陈洁, 胡章勇. 替加环素治疗多重耐药菌感染的药物监测[J]. 生命的化学, 2019, 39(3):521-526. DOI: 10.13488/j.smhx.20190012 .

[96]CC Zhou , F Huang , JM Zhang , et al. Population pharmacokinetics of tigecycline: a systematic review[J]. Drug Des Devel Ther, 2022, 16:1885-1896. DOI: 10.2147/DDDT.S365512 .

[97]N Armstrong , M Richez , D Raoult , et al. Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple′s disease[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2017, 1060:166-172. DOI: 10.1016/j.jchromb.2017.06.011 .

[98]AR Tunkel , R Hasbun , A Bhimraj , et al. 2017infectious diseases society of america′s clinical practice guidelines for healthcare-associated ventriculitis and meningitis[J]. Clin Infect Dis, 2017, 64(6):e34-e65. DOI: 10.1093/cid/ciw861 .

[99]夏利新, 毛知兰, 苏秋平, 等. 颅内鲍曼不动杆菌感染患者脑脊液中替加环素的药物浓度监测[J]. 中国处方药, 2021, 19(11):46-48. DOI: 10.3969/j.issn.1671-945X.2021.11.020 .

[100]梅升辉, 罗旭颖, 李倩, 等. HPLC-MS/MS测定替加环素脑脊液浓度及临床应用[J]. 中国药师, 2016, 19(1):21-25. DOI: 10.3969/j.issn.1008-049X.2016.01.006 .

[101]D Gardiner , G Dukart , A Cooper , et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials[J]. Clin Infect Dis, 2010, 50(2):229-238. DOI: 10.1086/648720 .

[102]国卫办医函. 关于印发碳青霉烯类抗菌药物临床应用专家共识等3个技术文件的通知[EB/OL]. [ 2023-02-01]. http://www.nhc.gov.cn/yzygj/s7659/201809/95f65ca473b44746b24590e94468b8ff.shtml.

[103]AC Kalil , ML Metersky , M Klompas , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society[J]. Clin Infect Dis, 2016, 63(5): e61-e111. DOI: 10.1093/cid/ciw353 .

[104]中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识编写组, 中国医药教育协会感染疾病专业委员会, 中华医学会细菌感染与耐药防控专业委员会. 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识[J]. 中华医学杂志, 2021, 101(36):2850-2860. DOI: 10.3760/cma.j.cn112137-20210219-00438 .

[105]周华, 周建英, 俞云松. 中国鲍曼不动杆菌感染诊治与防控专家共识解读[J]. 中国循证医学杂志, 2016, 16(1):26-29. DOI: 10.7507/1672-2531.20160006 .